A Compound represented by the following general formula (1), salts thereof or hydrates of the foregoing is a novel compound useful for treatment and/or prevention of diseases associated with thrombus formation, and which is safer with suitable physicochemical stability.
[wherein R
1a
, R
1b
, R
1c
and R
1d
each independently represent hydrogen, etc.; R
2
represents optionally substituted phenyl, etc.; R
3
represents optionally substituted C6-10 aryl, etc.; and Z
1
and Z
2
each independently represent hydrogen]
A Compound represented by the following general formula (1):
wherein R
1a
, R
1b
, R
1c
and R
1d
each independently represent hydrogen, etc.; R
2
represents optionally substituted phenyl, etc.; R
3
represents optionally substituted C6-10 aryl, etc.; and Z
1
and Z
2
each independently represent hydrogen
or salts thereof or hydrates of the foregoing.
We describe here a controlledapproach to C1-symmetrical cyclotriveratrylenes (CTVs). In this approach dimers are synthesized through Barluengaboroniccoupling (BBC) and after borylation, the last aromatic ring is introduced by a second BBC. After functional transformations of the trimers, the CTVs are formed using intramolecular SEAr.